Orally active inhibitor of lipocalin-type prostaglandin D synthase (L-PGDS) (Ki = 75 μM, IC50 = 95 μM). Inhibits the production of PGD2 from PGH2 in vitro, with no effect on PGE2 or PGF2α production.